ANICCA-Class II: For Investigators

A phase II trial assessing nivolumab in class II expressing microsatellite stable colorectal caner 

Change of Staff

If there is a change of staff working on the study please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the ANICCA-Class II Study Office.

Study Documents

Links to the current protocol, patient information sheet, informed consent form are provided below. If there has been a recent amendment to the study please ensure you have R&D approval before using these documents.

Other documents (e.g. amendments, case report form, serious adverse event Form, guidelines, GP Letter etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the ANICCA-Class II study office. 

Version Control Lists

The version numbers and dates of all documents currently used for the study are captured on a document version control lists below:

Case Report Form

Links to the current CRF are provided below.

Pharmacy Documents


Other Study Documents


No publications currently.

News and Events

There is no current news or events for this study.

Contact Details

Chief Investigator

Professor Gary Middleton 
Institue of Immunology and Immunotherapy
University of Birmingham
B15 2TT                                                                      

Tel: +44 (0) 121 414 7144                                             


ANICCA Class-II Study Office

Trial Coordinator:                                       Jessica Crook


Trial Monitor:                                              Karen James

Trial Management Team Leader:              Joshua Savage
Lead Statistician:                                        Lucinda Billingham                          
Trial Statistician:
                                         Wenyu Liu

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
B15 2TT


Telphone: +44 (0) 121 414 6754 (8am till 5pm Monday to Friday)

Serious Adverse Event Reporting



The University of Birmingham